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Abstract
MicroRNAs (miRNAs) are short 18–23 nucleotide long noncoding RNAs that
posttranscriptionally regulate gene expression by binding to mRNA. Our previ-
ous miRNA profiling of diffuse large B-cell lymphoma (DLBCL) revealed a
mutation in the seed sequence of miR-142-3p. Further analysis now showed that
miR-142 was mutated in 11 (19.64%) of the 56 DLBCL cases. Of these, one case
had a mutation in both alleles, with the remainder being heterozygous. Four
mutations were found in the mature miR-142-5p, four in the mature miR-142-
3p, and three mutations affected the miR-142 precursor. Two mutations in the
seed sequence redirected miR-142-3p to the mRNA of the transcriptional repres-
sor ZEB2 and one of them also targeted the ZEB1 mRNA. However, the other
mutations in the mature miR-142-3p did not influence either the ZEB1 or ZEB2
3′ untranslated region (3′ UTR). On the other hand, the mutations affecting the
seed sequence of miR-142-3p resulted in a loss of responsiveness in the 3′ UTR
of the known miR-142-3p targets RAC1 and ADCY9. In contrast to the mouse
p300 gene, the human p300 gene was not found to be a target for miR-142-5p.
In one case with a mutation of the precursor, we observed aberrant processing of
the miR-142-5p. Our data suggest that the mutations in miR-142 probably lead
to a loss rather than a gain of function. This is the first report describing muta-
tions of a miRNA gene in a large percentage of a distinct lymphoma subtype.
ª 2012 The Authors. Published by Blackwell Publishing Ltd. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
frequently occurring form of non-Hodgkin’s lymphoma
(NHL) and accounts for an estimated 30% of all NHL cases
worldwide [1, 2]. Moreover, DLBCL represents nearly 90%
of aggressive B-cell lymphomas in the Western world. It is
a heterogeneous disease, which consists of several histo-
logical subtypes, and if left untreated, it has an aggressive
and fatal clinical course [1]. Today, the combined use of
monoclonal anti-CD20 antibodies (rituximab) with
CHOP-like poly-chemotherapy regimens has significantly
altered the therapeutic landscape and improved clinical
outcome [3]. Nevertheless, elderly patients, young patients
with cofounding risk factors, or patients with early relapse
of disease still face significant challenges and have an unac-
ceptable low cure rate. Therefore, a better understanding of
the molecular pathways involved in DLBCL pathogenesis
and disease progression is needed to hopefully develop
better tailored therapeutic approaches.
According to the most recent World Health Organization
(WHO) lymphoma classification, DLBCL divides into
subtypes based on genetic, immunological, morphological,
and clinical features [1, 2]. Three molecular DLBCL subtypes
can be identified by gene expression profiling (GEP) that
correlates with clinical outcome [4]: germinal center B cell,
like (GCB) DLBCL; activated B cell, like (ABC) DLBCL; and
primary mediastinal B-cell lymphoma (PBML). The ABC-like
cases have a poorer prognosis [5] when compared with
GCB-like cases [6]. The latter occasionally features a translo-
cation involving the bcl-2 gene [4]. However, gene expression
data do not capture all the biological parameters that
influence diagnosis and response to therapy and are not yet
included in clinical decision-making processes.
Therefore, new biomarkers with either predictive value
or even therapeutic relevance are needed. MicroRNAs
(miRNAs) might be suitable candidates as they are viewed
as global regulators of almost all cellular pathways. They
are composed of 18–23 nucleotides and bind mostly to
target sequences within the 3′ UTR or in rare cases to the
coding region of their target mRNAs thereby inhibiting
protein expression. Some miRNAs are now recognized as
oncogenes or tumor suppressors, and the miRNA profile
can serve as a molecular signature of a particular tumor
(for review, see [7, 8]). In addition, miRNA expression is
associated with outcome in hematologic neoplasms and
correlates with survival of DLBCL patients treated with
rituximab-CHOP [9].
Deregulation of miRNA expression, for instance, via
deletion or amplification of miRNA genes has been
reported for a variety of tumors [10]. A germline muta-
tion in the seed sequence of miR-125a at position +8 has
been described [11] and was proposed to be a risk factor
for breast carcinoma. This study involved a cohort of
72 cases of breast carcinoma from Belgium, and 282
Belgian and 587 Caucasian controls from the United
States of America [12]. However, a recent study involving
a total of 3145 breast cancer cases and 4114 controls
showed no mutation at this miRNA [13]. Relatively little
is known about somatic mutations directly affecting the
mature miRNAs. In the complete sequence analysis of a
single patient with acute myeloid leukemia, no mutations
within the miRNAs were found [14]. A somatic point
mutation in the precursor of human miR-33b not affect-
ing the mature miRNA was observed in one of the 48
medulloblastoma cases, a highly aggressive brain tumor
[15]. The sequence analysis of Colo-829, a cell line
derived from a patient with a malignant melanoma,
revealed a single point mutation in the central region of
the stem loop structure of hsa-miR-518d [16]. Two cell
lines and one primary pancreatic carcinoma specimen
revealed two mutations each in the pri-miRNA regions of
the two oncogenic miRNAs miR-21 and miR-155, again
not affecting the mature miRNAs [17]. Permuth-Wey and
colleagues recently published data suggesting that a
single-nucleotide polymorphism in the precursor of
miR-146a was associated with an increased risk for glio-
blastoma [18]. Robbiani et al. reported a reciprocal
translocation in mature B-cell leukemia involving the
miR-142 gene locus and the c-myc gene in transgenic,
p53-deficient mice overexpressing AID [19]. A corre-
sponding translocation in human aggressive B-cell leuke-
mia involving the miR-142 locus (there called the bcl3
gene) and c-myc was described earlier [20]. In both cases,
the translocation affected the levels of c-myc transcript,
whereas point mutations in the miR-142 locus were not
reported. In contrast to the scant information concerning
mutations affecting mature miRNAs, polymorphisms
in the binding sites for miRNAs have been reported to a
larger extend (see, for instance, [21, 22]).
We had previously compared the miRNA profile of
Epstein–Barr virus (EBV)-positive versus EBV-negative
DLBCL by high-throughput sequencing of a miRNA
cDNA library [23]. In one of the cases, we noted a muta-
tion from T to C at position 8 in the seed sequence of
miR-142-3p that was confirmed by DNA sequencing of
the original tumor specimen. In that study, we found that
various cellular miRNAs were up- or downregulated at
least twofold due to EBV infection, but no significant
change in the levels of miR-142-3p or -5p was observed
[23]. MiR-142-3p is downregulated in acute myeloid
leukemia [24] and inhibits migration and invasion of
hepatocellular carcinoma lines [25]. Recently, the mRNAs
coding for the small GTP-binding protein RAC1 and the
adenylate cyclase 9 protein (ADCY9) were shown to be
targets for miR-142-3p [25, 26]. RAC1 induction
142 © 2012 The Authors. Published by Blackwell Publishing Ltd.
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stimulates invasiveness of T-lymphoma cells [27] and is
associated with poor prognosis of hepatocellular carci-
noma [28]. ADCY9 activates RhoA, another GTPase with
tumorigenic potential (reviewed in [29]). However, the
function of ADCY9 in lymphomas is unclear. Recently,
the mouse p300 gene was identified as a target for murine
miR-142-5p [30].
The mutation in the seed sequence of miR-142-3p as
identified by us generated three novel potential binding
sites on the 3′ UTR of the mRNA coding for the tran-
scriptional repressor ZEB2 (SIP1), which is, on one hand,
involved in the switch of EBV latent to lytic replication
[31], but also plays a role in cancer biology by regulating
E-cadherin expression and the ensuing epithelial-to-mes-
enchymal transition (EMT) [32]. Here, we show that 11
of 56 DLBCLs suffered mutations in the gene-encoding
miR-142 affecting either miR-142-5p, miR-142-3p, or the
87 nt precursor encompassing both miRNAs. Some of the
miR-142-3p mutants acquire novel target regulatory
functions vis-a`-vis the ZEB1 or ZEB2 transcriptional
repressors while some lose their ability to downregulate
the known targets RAC1 and ADCY9. In contrast to the
regulation of the mouse p300 gene/mRNA by miR-142-
5p, we were not able to demonstrate a downregulation of
human p300 by miR-142-5p, neither by testing the
3′ UTR nor by expression of miR-142 in human cells.
Materials and Methods
Patient samples
Tumor specimens of 40 DLBCL patients were obtained
from the Institute of Pathology, Campus Benjamin Frank-
lin, Charite´-Universita¨tsmedizin Berlin, Germany (see
Table S1). In addition, 16 DLBCL samples were obtained
from the Institute of Surgical Pathology, University Hos-
pital Zu¨rich, 8093 Zu¨rich, Switzerland. The diagnosis was
confirmed by histopathology review according to the
WHO classification criteria. Informed consent was
obtained from all patients, and the use of the materials
was approved by the local ethics committees.
Immunohistochemistry
Sections from FFPE (formalin-fixed, paraffin-embedded)
blocks were deparaffinized and antigenicity was retrieved
by cooking in citrate buffer (100 mmol/L) for 5 min (BCL6
antibody) or 2 min (CD10 and IRF4 antibodies). Staining
was performed using mouse monoclonal antibodies against
BCL6 (1:50; Clone PG-B6p, Dako, Denmark), CD10 (1:25;
Novocastra, Leica Microsystems, Germany), and IRF4
(1:25, clone Mum1p), kindly provided by B. Falini (Insti-
tute of Hematology, University of Perugia, Perugia, Italy).
Binding was visualized with the APAAP Mouse REAL
Detection System (Dako, Denmark) for the anti-CD10
antibody and REAL Detection System, Alkaline Phospha-
tase/RED (Dako, Denmark) for detection of anti-BCL6,
and anti-IRF4 antibodies.
Fluorescence in situ hybridization
Interphase fluorescence in situ hybridization (FISH) was
performed on FFPE tissues using break-apart assays for
MYC, BCL2, and BCL6 (all from Dako, Denmark), and
LSI MYC/IGH and LSI BCL2/IGH dual-color dual-fusion
translocation probes (all from Abbott/Vysis, USA). For
signal detection an Axio Imager Z1 (Zeiss, Germany)
together with Isis software (version 5.3.1, MetaSystems,
Germany) was employed.
Cell lines and plasmids
HEK 293T and U2932 (provided by P. Angel, identity
confirmed by Schmitt and Pawlita [33], DKFZ, Heidel-
berg, Germany) were cultivated at 37°C, 5% CO2 in
DMEM (Dulbecco’s modified Eagle medium) or RPML
(Roswell Park Memorial Institute) 1640 medium supple-
mented with 10% fetal bovine serum (Invitrogen, Carls-
bad, CA) and 19 antibiotics (Sigma, St. Louis, MO) as
described [24]. The vector pcDNA4hismaxCZEB2 for the
expression of full-length ZEB2 [31] was a generous gift
from Janet E. Mertz, University of Wisconsin School of
Medicine and Public Health, Madison, WI, USA. The dual
luciferase reporter plasmid pMIR-RL has been described
elsewhere [23]. The 3′ UTR fragments of RAC1 (accession
number: NM_018890), ZEB1 (accession number: NM_
001128128), ZEB2 (accession number: NM_001171653),
and ADCY9 (accession number: NM_001116) were poly-
merase chain reaction (PCR) amplified from human testis
cDNA and ligated into the corresponding SacI and SpeI
sites of pMIR-RL using the primers Rac1 SpeI 5′-GGG
GTG TGT GTG ATC AAA GG-3′ and RAC1 SacI 5′-CCA
CAA TTC TGC AAC TGT-C3′; ZEB1 SpeI 5′-GAT AAC
TAG TTC TAG AAG GAA AAT AAA TTC TAA TTG AT-
3′ and ZEB1 SacI 5′-GAT AGA GCT TAA GAC ATC AAA
TAT TAG AAA TTA CTA-3′; ZEB2 SpeI 5′-GAT AAC
TAG TGT ACA GTG TTA AGG CCT AAA AAC TGT
G-3′ and ZEB2 SacI 5′-GAT AGA GCT CGT ACA GAA
CTC ATT AAC TAC ATT CTT-3′; ADCY9 SpeI 5′-GAT
AAC TAG TTC TAG AAG GAA AAT AAA TTC TAA
TTG AT-3′ and ADCY9 SacI 5′-GAT AGA GCT CTA
AGA CAT CTA AAT ATT AGA AAT TAC TA-3′. The
human p300 3′ UTR (accession number: NM_001429) was
amplified using the primers p300 SpeI 5′-GGA CTA GTG
GCT GAG GCC TGT GAA GCC-3′ and p300 SacI 5′-CGA
GCT CCC CCT TTT GTC CTC TGG-3′.
© 2012 The Authors. Published by Blackwell Publishing Ltd. 143
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For the mutations of the binding sites of the miR-142-
3p mutants in the 3′ UTR of ZEB2, the sites 1–3 as shown
in Figure S1 were sequentially mutated as described [34]
using the primer pairs ZEB2 mut1 5′-ACT CTA CTT ATG
TAT AGA TCT AAA CTT TAA AAA AC-3′ and ZEB2
mut1rev 5′-GTT TTT TAA AGT TTA GAT CTA TAC
ATA AGT AGA GT-3′; ZEB2 mut2 5′-TTT AAT TGC
TCG AGA TCT AAT GCA TCA GTA TTA-3′ and ZEB2
mut2rev 5′-TAA TAC TGA TGC ATT AGA TCT CGA
GCA CAT TAA A-3′; ZEB2 mut3 5′-CAT TTT AAA AAG
GTG CCC GAG ATC TCA TAC ATC AG-3′ and ZEB2
mut3rev 5′-CTG ATG TAT GAG ATC TCG GGC ACC
TTT TTA AAA G-3′. The binding sites for the mutant
miR-142-3p-m1 and -m2 in the ZEB1 3′ UTR were
mutated with the primers 5′ ZEB1-mut1-pmlI 5′-GTG
AGA ACT TCT GCC ACG TGA AAT TCC CTT CA-3′
and 3′ ZEB1-mut1-pmlI 5′-TGA AGG GAA TTT CAC
GTG GCA GAA GTT CTC AC-3′; 5′ ZEB1-mut2-Bgl 5′-
TGT GAT TCC TGT TAG ATC TTG TGT AAA GTA-3′
and 3′ ZEB1-mut2-Bgl 5′-TAC TTT ACA CAA GAT CTA
ACA GGA ATC ACA-3′, respectively. The mutations were
detected using novel restriction sites (underlined) intro-
duced in the seed region for miRNA binding.
Sequence analysis
Genomic DNA from the Swiss tumor samples were puri-
fied from FFPE sections by the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. In case of the German tumor samples,
genomic DNA was extracted from fresh frozen tumor spec-
imens, tonsils, and normal healthy peripheral blood mono-
nuclear cells by standard protocols; miRNAs were purified
using the miRVana miRNA Kit (Ambion, Austin, TX)
according to the manufacturer’s protocols. For the amplifi-
cation of the miR-142 gene with the proof-reading Phusion
DNA polymerase (New England Biolabs, Frankfurt/M.,
Germany), the primers 5′ miR142 EcoRI 5′-GGA ATT
CGG GAT CTT AGG AAG CCA CA-3′ and 3′ miR142
Bam HI 5′-CGG GAT CCA TGG AGG CCT TTC AGG
CAT-3′ were used. A typical 50 lL reaction consisted of
50–100 ng tumor DNA, 50 pmol each of the 5′ miR142
EcoRI and 3′ miR142 Bam HI primers, and 1 U of the
Phusion polymerase. The following were the PCR settings:
Step 1: 98°C, 10 min; Step 2: 98°C, 1 min; Step 3: 58°C,
1 min; Step 4: 72°C, 1 min; repeat Step 2 through 4, 35
times; Step 5: 72°C, 10 min. T/A-tailing was done using
Taq polymerase (Sigma, Munich, Germany) in a 10 lL
reaction using 5 lL of the above reaction, 2 lL dATP
(10 mmol/L), and 5 U Taq polymerase. The resulting PCR
products of 314 bp were T/A cloned into the vector
pGEM-T Easy (Promega, San Luis Obispo, CA). For each
sample, at least 10 clones were sequences using T7 and Sp6
primers. For those samples where mutations were found,
additional samples were sequenced. For expression in
eukaryotic cells, the EcoRI-BamHI-fragments were excided
from the pGEM clones and inserted into the corresponding
sites of the vector pSG5 (Agilent, Bo¨blingen, Germany).
Generation of ZEB2 antibodies
A rabbit antiserum against the C-terminus of ZEB2 was
generated as described [34]. Shortly, a fragment encoding
the 112 C-terminal amino acids of ZEB2 was PCR ampli-
fied from vector pcDNA4hismaxCZEB2 (see above) using
the primers ZEB 5′ Eco (TAT GAA TTC ACC GAG CTG
CTG ATG AAC CGG GC) and ZEB 3′ Sal (GCA GTC GAC
TTA CAT GCC ATC TTC CAT ATT GTC TTC C) and
cloned into the EcoRI/SalI sites of pGEX®-4T-1 (Promega,
Mannheim, Germany). The corresponding GST-fusion
protein was purified from Escherichia coli BL21/DE3 and
used for the immunization of New Zealand white rabbits.
For Western blotting, the serum was used at a dilution of
1:50 and visualized by the enhanced chemoluminescence
(ECL) method as described [24]. For the detection of
ZEB1, a polyclonal rabbit serum (H-106, sc-25388) was
obtained from Santa Cruz, Heidelberg, Germany. A rabbit
antibody against p300 (N-15) was purchased from Santa
Cruz Biotechnology, Heidelberg, Germany (order #sc-584).
Transfection and luciferase assays
Plasmid transfections for luciferase assays in 293T cells were
performed with 0.2 lg of reporter construct and 0.8 lg miR-
NA expression plasmid in a 24-well plate using Nanofectin
transfection reagent (PAA, Coelbe, Germany) as described by
the manufacturer. Luciferase activity was measured 48 h post
transfection using the Dual Luciferase Reporter Assay System
as described by the manufacturer (Promega).
Northern blot
Total RNA was extracted from cells using TriZol Reagent
(Invitrogen, Carlsbad, CA) following the vendor’s recommen-
dations. Total RNA measuring 25 lg was routinely electro-
phoresed through 12% urea-polyacrylamide gel and then
electroblot transferred to nylon membrane Hybond XL
(Amersham) for 1 h at 2 mA/cm2. The membrane was
EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimid) chemi-
cally cross-linked as described [24]. Blots were hybridized with
radioactive labeled antisense probe overnight and then washed
twice for 15 min with 59 SSC (saline-sodium citrate), 1%
SDS (sodium dodecyl sulfate) and twice for 15 min with
19 SSC, 1% SDS. As radioactive probes, we used appropri-
ate RNA probes labeled with miRVana Probe construction
kit (Ambion) according to the manufacturer’s instructions.
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MicroRNA transfection assay and Western
blot
MicroRNA expression using RNA mimics was done by
transfecting 0.75 nmol per 106 cells miR-142-3p-wt, miR-
142-3p-m1, or miR-142-3p-m2 (Applied Biosystems/
Ambion, Darmstadt, Germany). U2932 cells were transfect-
ed with lipid-based siPORT™ NeoFX™ Transfection Agent
(Ambion) according to manufactures recommendation.
Anti-miR miRNA Inhibitors – Negative Control #1 (Ambi-
on) served as mock transfectant. After transfection cells
were cultivated for 2 days, counted and protein extracts
were generated by adding sample buffer (Promega). Protein
levels were normalized according to the counted cell num-
ber. Western blot was performed as previously [24]. The
relative levels of protein were determined by densitometric
analysis of the signals for the tested proteins in comparison
with the amount of b-actin stained on the same membrane
with a commercially anti-human b-actin antibody (Sigma,
Munich, Germany). The relative level of protein was deter-
mined from the scanned blots using the “Quantity One”
software (BioRad Life Sciences, Heidelberg, Germany).
Results
Mutations affecting miR-142 are found in
20% of DLBCL analyzed
In a previous study, we found no change in the expres-
sion levels of both miR-142-5p and -3p when we
compared EBV-positive versus EBV-negative cases of
DLBCL where both miR-142-5p and -3p were expressed
at about equal ratios [24]. However, we detected a muta-
tion affecting the seed region of miR-142-3p, which gen-
erated a potential novel binding site in the 3′ UTR of the
ZEB1 mRNA and three potential novel binding sites in
the 3′ UTR of the ZEB2 mRNA. Because ZEB2 plays a
role in tumorigenesis [32], we wanted to see whether
miR-142 was mutated in a larger number of DLBCL
cases. We thus analyzed a total of 56 cases of DLBCL for
the presence of mutations affecting miR-142 and also
assayed the regulation of the above-mentioned 3′ UTRs
vis-a`-vis the mutant miRNA. We obtained PCR products
from 56 cases that were subsequently analyzed. In the
controls (DNA of 20 healthy blood donors and of 10
benign tonsils), no mutation affecting miR-142 was
detected (data not shown). In addition, the sequences of
the miRNAs obtained from the miRNA profiling data of
10 cases each of prostate carcinoma and normal prostate
tissue that were previously obtained [35] also showed no
mutation in the mature miR-142-3p or -5p (J. Szczyrba,
pers. comm.). However, as depicted in Figure 1, we found
single mutations within the 87 nt long precursor sequence
for miR-142 in 11 (19.64%) of 56 cases of DLBCL. Of
those, four single point mutations were present in the
mature miR-142-5p or -3p. Two point mutations each
affected the seed sequences of miR-142-5p (mutants des-
ignated -m3 and -m4 in Fig. 1) or -3p (mutants desig-
nated -m1 and -m2 in Fig. 1). The mutation designated
m2 was detected in two samples. The mutations in m5
and m6 affected the mature miR-142-3p, and mutations
in -m7 and -m10 were present in the mature miR-142-
5p, but outside the seed sequence. Three additional muta-
tions were found in the precursor outside the mature
Figure 1. Mutations of miR-142 found in DLBCL. The sequence of the wild-type (WT)miR-142 precursor is shown on top, sequences of the
mature miR-142-5p and -3p are underlined with the seed sequences shown in boldface. The mutations found in individual patients are shown
below the wild-type sequence. Note that mutants m10 and m11 were found in one lymphoma.
© 2012 The Authors. Published by Blackwell Publishing Ltd. 145
W. Kwanhian et al. MiR-142 Mutations in DLBCL
miRNAs. Of those, the mutant designated m9 had two
base changes flanking miR-142-5p, and m10 had three
mutations (two flanking and one mutation in the mature
miR-142-5p outside the seed sequence). The mutations
m10 and m11 occurred in one lymphoma. The mutations
were at different sites within the miR-142 precursor;
apparently, this patient suffered two individual mutations.
In this sample, some wt-sequences were also detected
which were probably derived from nontransformed stro-
mal cells. We had access to normal tissue in four cases
that featured a mutation in miR-142 (patients with
mutants m3, m7, m9, and m10/11). Sequence analysis of
the normal tissues showed no mutations indicating that
the mutations in the tumors were probably somatically
acquired. However, a larger number of patient’s samples
with mutations will need to be analyzed in the future.
We then asked whether the presence of the mutations
correlates with clinical parameters or the lymphoma sub-
type. Of the 11 lymphomas with miR-142 mutation, five
were of ABC and six of GCB type as determined by
immunohistochemistry (IHC) [36]. Thus, the occurrence
of the miR-142 mutations cannot be correlated to a cer-
tain DLBCL subtype. The same holds true for the differ-
ent miR-142 mutations found. There is no association
with either GCB or non-GCB subtype of DLBCL. We
found no correlation to any parameter like age at lym-
phoma onset or gender. In addition, we could not iden-
tify any link to clinical data such as response to treatment
or survival. However, all lymphomas harboring mutations
in miR-142 showed expression of IRF4/Mum1 including
those of GCB subtype by IHC (Table S1). IRF4/Mum1 is
expressed in a relatively large number of malignant
lymphoma and reported to be associated with good
prognosis for B-cell chronic lymphocytic leukemia
(B-CLL) (reviewed in [37]). However, another report
found that expression of IRF4 was associated with a poor
prognosis for B-cell chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma (SLL) [38]. So far, there is
no clear correlation between the expression of IRF4 and
the prognosis of DLBCL [39]. The percentage of muta-
tions found in the sequence reactions of the individual
lymphomas is shown in Table S2.
Point mutations in the seed sequence of
miR-142-3p generate novel target sites in
the ZEB1 and ZEB2 3′ UTRs
A bioinformatical analysis using the “Custom TargetScan”
algorithm (http://www.targetscan.org/) employing the
mutated seed sequence of miR-142-3p-m1 shown in
Figure 1 indicated that the 3′ UTR of the ZEB2 mRNA
contained three potential novel binding sites for m1. This
is shown in Figure S1. We therefore obtained the com-
plete 3′ UTR of ZEB2 by PCR amplification and subse-
quently generated a luciferase reporter construct as
previously described [24]. The luciferase reporter analysis
shown in Figure 2A, right panel, demonstrated that m1
but not the miR-142-3p wild-type nor the miR-142-3p-
m3 mutant had a significant effect on the reporter. We
observed a significant downregulation of the reporter
construct by m1 by about 52% (P = 3.5E-08). None of
the miR-142 constructs had an effect on the empty pMIR
reporter vector (Fig. 2A, left panel). Next, we analyzed
which of the potential binding sites on the ZEB2 3′ UTR
were used by m1. For this purpose, either single muta-
tions or the possible combinations of the potential
Figure 2. Downregulation of the ZEB2 3′ UTR by miR-142-3p mutant m1. (A) An empty luciferase reporter (“pMIR”) or a reporter containing the
ZEB2 3′ UTR (“pMIR-ZEB2-3′ UTR”) and expression vectors for miR-142-3p and the mutants -m1 and -m3 were coexpressed in HEK 293T cells as
indicated. (B) Luciferase reporter vectors containing mutated binding sites in the ZEB2 3′ UTR were tested for responsiveness to miR-142-m1.
Columns represent the mean values of three independent experiments carried out in duplicate (± SEM).
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binding sites were generated. Mutations of the single sites
had no effect (Fig. 2B, left panel), and only the mutation
of all three potential binding sites resulted in a complete
loss of reactivity indicating that all three sites were used
(Fig. 2B, right panel). The sequential introduction of the
mutations led to an increased loss of reactivity as com-
pared with the single mutants or the wt-3′ UTR indicat-
ing that there was a cooperative effect of the binding
sites.
We then assayed the effect of m1 and m2 on the ZEB1
3′ UTR and found that only m1 downregulated this
reporter. The mutation of the two potential binding sites
for m1 on the ZEB1 3′ UTR revealed that binding site 1
was used by the mutants (Fig. 3). As about 15% of all
DLBCLs are EBV positive, we asked whether any of the
EBV-encoded miRNAs (for review, see [40]) could poten-
tially target the ZEB1 or ZEB2 3′ UTR. The “TargetScan”
algorithm predicted binding sites for both EBV-miR-
BART7 and -BART22 on the ZEB2 but not on the ZEB1
3′ UTR. However, neither of the two EBV-miRNAs had
any effect on the empty vector or the pMIR-ZEB2-3′
UTR construct (Fig. S2).
Seed-sequence mutations of miR-142-3p
result in downregulation of ZEB2 protein
expression
To show that the mutation in the miR-142-3p-m1 indeed
affect the expression level of their mRNA targets, polyclonal
rabbit antibodies against the ZEB2 protein were generated
using a bacterially expressed GST-ZEB2 fusion protein as
previously described [41]. The immune serum was tested in
cell extracts of 293T cells expressing a haemagglutinine
(HA)-tagged ZEB2 expression vector [31] as control.
Expression of the recombinant ZEB2 could both be verified
using a HA-specific antibody as well as the ZEB2-specific
Figure 3. Downregulation of the ZEB1 3′ UTR by miR-142-3p-m1 but
not m2. (A) The empty luciferase reporter construct (pMIR, left panel)
or a reporter containing the wild-type ZEB1 3′ UTR (right panel) was
coexpressed with vectors for miR-142-3p and the mutants -m1, -m2,
and empty pSG5 vector as indicated. (B) Reporter vectors with
mutated binding sites in the ZEB1 3′ UTR were coexpressed in HEK
293T cells with expression vectors for miR-142-wt, -m1, and -m2 in
the indicated combinations. Coexpression of pSG5 served as control.
Mean values were derived from three independent experiments
carried out in duplicate (± SEM).
Figure 4. Downregulation of the ZEB2 protein
by miR-142-3p mutant m1. HEK 293T cells (A)
were transfected with empty pSG5 vector,
pSG5-miR-142-3p-wt, or the m1 mutant as
indicated. The levels of b-actin stained on the
same blot were used as input control. The
graph shown in (C) depicts the quantification
of three individual assays. The DLBCL cell line
U2932 was transfected with RNA mimics using
the miR-142-3p-wt or a scrambled RNA mimic
(“NC”) as controls as indicated (C). The graph
in (D) depicts the quantification of the
downregulation of ZEB2 in four individual
experiments. ZEB2 was visualized by Western
blotting using a polyclonal rabbit serum
directed against the C-terminus of ZEB2.
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rabbit serum (data not shown). We then tested the expres-
sion level of ZEB2 in 293T cells transfected with empty vec-
tor, the pSG5-miR-142-wt vector, and pSG5-miR-142-3p-
m1. As shown in Figures 4A and S5, the vector expressing
miR-142-3p-wt did not change the levels of ZEB2 in 293T
cells, whereas the expression of the mutant m1 clearly led
to a reduction of about 40% in the amount of endogenous
ZEB2. We then analyzed the EBV-negative U2932-DLBCL
cell line for the influence of miR-142-3p-wt or the -m1
mutant. Here, we used a RNA mimic either for the wild-
type or the m1 mutant because the transfection efficiency
using pSG5 expression vectors was too low (data not
shown). As shown in Figure 4B, neither the negative con-
trol (“NC”) nor the wild-type mimic changed the level of
ZEB2 while we observed a reduction of about 30% using
the mutant m1 mimic.
We then used a commercially available antiserum
against ZEB1 (H-106, Santa Cruz) and found no expres-
sion of this protein in the U2932 cell line (data not
shown). Therefore, the impact of the miR-142 mutants
on ZEB1 expression was not pursued further.
Mutations in the seed sequence of miR-142-
3p result in a loss of responsiveness of the
RAC1 and the ADCY9 3′ UTRs
It was previously shown that the 3′ UTR of the mRNAs for
the small GTP-binding protein RAC1 as well as the
ADCY9 represents targets for miR-142-3p [18, 26]. We
therefore asked whether the mutation in the seed sequence
of miR-142-3p-m1 or -m2 had an influence on the down-
regulation of RAC1 by this miRNA. For this purpose, a
luciferase reporter construct featuring the 3′ UTR of RAC1
was generated. When assayed with the various expression
vectors, we found that miR-142-3p-wt downregulated the
luciferase activity by about 35% (P = 2.4 exp 7), while
both -m1 and -m2 had lost their ability to influence the
RAC1 3′ UTR (P = 0.23 and P = 0.133, respectively)
(Fig. 5A). Furthermore, we found that both mutants also
lost their potential to downregulate the ADCY9 3′ UTR,
while miR-142-3p-wt clearly had an effect toward this 3′
UTR (P = 0.000021 for miR-142-3p-wt, P = 0.027 for
-m1, and P = 0.28 for -m2) (Fig. 5B).
Mutations in miR-142 affect correct
processing
We then assayed whether the mutants that did not affect
the mature miR-142-5p or -3p showed any difference in
their processing. Mutants were transiently expressed using
the pSG5 expression vector and analyzed by Northern blot-
ting. For reasons unknown, we were not able to sub-clone
the mutant m6 into the pSG5 expression vector despite
repeated attempts. As shown in Figure 6, all mutants with
the exception of m9 were properly processed to the mature
miR-142-5p or -3p. We initially observed no or low signals
for miR-142-m3-5p, m7-5p, and m10-5p. These were
therefore reanalyzed with perfectly matching antisense
probes. As shown in Figure S3, these 5p-mutants were also
expressed. We noted a more complete conversion of the
-3p precursors as compared with the -5p precursors. The
mutant m9 showed correct processing to the mature miR-
142-3p but exhibited a somewhat larger “mature” miR-
142-5p. To ascertain that the miR-142-5p and the other
mutants were processed correctly, we carried out a North-
ern blot analysis comparing the transiently expressed miR-
142-5p-wt, -m1, -m3, and -m9 along with RNA from
U2932 DLBCL cells [24]. As shown in Figure S4, miR-142-
5p-wt and m1 migrated to the same position as the endoge-
nous miR-142-5p from the U2932 cells. As already shown
in Figure 6, m3 was not recognized using the probe for
miR-142-5p-wt, and the m9 mutant again migrated to a
higher position. The correct processing to miR-142-3p was
previously demonstrated [42].
Human p300 is not a target for miR-142-5p
Sharma et al. had previously shown that the mouse p300
gene is a target for miR-142-5p. We therefore tested the
Figure 5. MiR-142-3p mutants m1 and m2 lose their potential to
downregulate the RAC1 and ADCY9 3′ UTRs. (A) Luciferase
constructs featuring the binding regions for miR-142-3p on the RAC1
3′ UTR (“pMIR-RAC1-3′ UTR”) (A) or the ADCY9 3′ UTR (B) were
assayed with empty pSG5 and pSG5 expression vectors for miR-142-
3p-m1 and -m2 after cotransfection into HEK 293T cells in the
indicated combinations. The graphs represent eight independent
assays carried out in duplicate (± SEM).
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3′ UTR of the human p300 gene (accession number
NM_001429) for its responsiveness to miR-142-5p-wt and
of the mutants m1 (mutation in the miR-142-3p), m3
(mutation in the miR-142-5p seed sequence), and the
incorrectly processed 5p mutant m9. As shown in
Figure 7A, the p300 3′ UTR was not responsive to either
the miR-142-wt or any of the mutants, while the RAC1
3′ UTR assayed in parallel was clearly downregulated by
miR-142-wt. The various plasmids were also transiently
transfected in 293T cells and tested for their ability to
downregulate the p300 protein. As shown in Figure 7B,
the p300 protein was not affected by the expression of
either miRNA as compared with the empty vector
control. The mature human and the mouse miR-142-5p
are identical. The alignment of the predicted and known
binding sites for miR-142-5p in the human and the
mouse p300 3′ UTRs, respectively, are shown in Fig-
ure 7C. As can be seen, the mouse sequence is divergent
immediately 5′ to the seed sequence from the human gene
which might explain this discrepancy.
Discussion
To the best of our knowledge, this is the first report dem-
onstrating that mutations affecting the mature sequence
of a miRNA occur in a sizable proportion of a given lym-
phoma subtype. In particular, we observed both a gain of
function and a loss of function caused by this miRNA
mutation. We could clearly demonstrate the downregula-
tion of the ZEB2 mRNA by the miR-142-3p mutant m1
(Fig. 1) both in the reporter assays using the ZEB2
3′ UTR (Fig. 2) and on the ZEB2 protein level (Fig. 3).
We could also demonstrate an effect of the mutants miR-
142-3p-m1 and -m2 on the 3′ UTR of the ZEB1 mRNA.
As ZEB1 was not detectable with commercially available
antibodies in the U2932 DLBCL cell line assayed, we did
not further test the effect of the mutants on ZEB1 pro-
tein. However, as the mutations occurred both in the
mature miR-142-5p and -3p form, we assume that the
observed gain of function for miR-142-3p on the ZEB1
or ZEB2 3′ UTR was a fortuitous event. At this time, we
do not know whether this “gain of function” is relevant
for the induction of DLBCL. However, we wanted to
show that the mutated miRNA was functional toward its
novel target but unable to downregulate known targets
like RAC1 or ADCY9 (see also below). In addition, there
was no significant difference in the levels of ZEB1 or
ZEB2 mRNA in the tumors analyzed (data not shown).
Conversely, we were able to demonstrate that the
mutations in the seed sequence of miR-142-3p destroyed
the ability of the miRNA to inhibit the RAC1 mRNA.
RAC1 is a member of the Rho family of small GTPases
and has been strongly implicated in tumorigenesis [43,
44]. It is involved in B-cell signaling through the CD40
receptor after activation of the RAS pathway [45] and
was found to be activated in anaplastic large T-cell
lymphomas [46]. RAC1 was shown to be a target of
miR-142-3p in hepatocellular carcinoma cells [26]. A
Figure 6. Expression of miR-142 mutants. The various miR-142-3p, -5p, or precursor mutants were expressed in HEK 293T cells. The expression
of miR-142-3p m1 and m2 (A and C) or -5p (B) was assayed by Northern blotting using the indicated probes. The position of the precursor and
the mature miRNAs are also shown. The bottom lane shows the band of the tRNA input control.
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Figure 7. The human p300 mRNA is not a target for miR-142-5p. (A) Luciferase constructs featuring the binding regions for miR-142-3p on the
p300 3′ UTR (“pMIR-p300-3′ UTR”) and the empty pMIR-RNL-TK vector were cotransfected with the indicated pSG5 miR-142 expression vectors.
The pMIR-RAC1-3′ UTR reporter (see Figure 5) served as a positive control. The graphs represent four independent assays carried out in duplicate
(± SEM). (B) HEK293T cells were transiently transfected with the indicated pSG5 miR-142 expression vectors and assayed 48 h after transfection
in a Western blot. p300 was visualized by the ECL method using a rabbit antibody and an appropriate secondary antibody. The level of b-actin
served as a loading control. (C) Comparison of the known mouse p300 and the putative human p300 binding site for miR-142-5p. The seed
sequence is indicated by bold letters, the binding region for miR-142-5p by a bar.
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separate report demonstrated that overexpression of
RAC1 in p53-deficient B- and T-lymphoma cells resulted
in an increased lymphoma cell proliferation [18]. Another
recent report showed that RAC1 and the proto-oncogene
BCL-2 form a complex and that RAC1 supports the
antiapoptotic activity of BCL-2 [47]. BCL-2 is sometimes
activated by chromosomal translocations in DLBCL [48].
It is thus conceivable that at the seed-sequence mutations
in miR-142-3p result in a release of RAC1 suppression
with a subsequent block in apoptosis, for instance via
binding to BCL-2. It is thus conceivable that some of the
mutations described in this communication contribute to
the induction of DLBCL via a loss of RAC1 inhibition by
the mutated miR-142-3p.
The two mutants m1 and m2 which show a “gain of
function” vis-a`-vis the ZEB1 and ZEB2 3′ UTRs also lose
their ability to downregulate a second known target of
miR-142-3p, the ADCY9 3′ UTR. A reduced inhibition of
ADCY9 by the mutated miR-142-3p would result in
increased cAMP levels. For DLBCL, it was shown that
increased levels of cAMP are proapoptotic in DLBCL. An
upregulation of cAMP levels via a reduced inhibition of
PKA targeting is thus counterintuitive to its possible role
in DLBCL tumorigenesis. Zhnag et al. have shown that
high levels of miR-375 and low levels of miR-142-5p are
a predictor for the outcome of gastric carcinoma [49].
Furthermore, reduced levels of miR-29a and miR-142-3p
are shown to promote growth of acute myeloid leukemia
cells, while overexpression leads to a differentiation of
myeloid cells with reduced growth properties [50]. At
least in some cases of DLBCL, the mutations in miR-142-
3p/5p might also influence the tumor cell growth via
reduced differentiation.
The aim of the experiments was to show that both a gain
of function and a loss of function can be observed for the
mutants tested. We did not observe mutations in other
miRNAs, which indicates that the mutations are specific
for miR-142. We again hypothesize that the miR-142
mutations will most likely result in a loss rather than a gain
of function. The nature of the genes that are regulated by
miR-142 in DLBCL is unknown and needs to be elucidated.
Lv et al. have shown that miR-142-3p plays an oncogenic
role in T-lineage acute lymphoblastic leukemia (T-ALL)
[51]. We have also found a downregulation of miR-142-3p
in EBV-positive nasal NK/T-cell lymphoma [52]. On the
other hand, miR-142 might have a tumor-suppressive role
in B cells, and the loss of function could then contribute to
the induction of DLBCL.
We also analyzed the expression levels of the cloned
miR-142 genes and found no obvious change in the
expression of either miR-142-3p or -5p in the various
clones (Fig. 6). In the case of miR-142-5p-m9, we
observed aberrant processing of the miRNA which led to
the generation of a larger final product. Because there are
no confirmed human miR-142-5p targets, it was not pos-
sible to test whether the larger product (or the other
mutants affecting the mature miR-142-5p) was still able
to regulate a potential target. In addition, it is unclear
whether this aberrant miRNA still contained the complete
sequence present in miR-142-5p or whether, for instance,
the 5′ nucleotides essential for target recognition were
absent. It is possible that the addition of nucleotides at
the 5′ end also leads to a change in target recognition,
most likely in the loss of recognition of (a) target(s).
Finally, when we assayed some of the miR-142-5p
mutants on the human p300 3′ UTR, we did not find a
downregulation by either the wild-type or the mutant
miRNAs. Likewise, the p300 protein was not reduced in
transiently transfected cells. This is in contrast to recently
published data which identified the 3′ UTR of the mouse
p300 gene as a target for miR-142-5p [30].
Lohr et al. described the whole exome sequencing of pro-
tein-encoding genes in 55 cases of DLBCL [53]. They found
a variety of mutated genes, for example, MYD88, CARD11,
or EZH2 [53]. They show that while some genes like bcl2
were probably mutated due to the activity of the AID
(activation-induced cytidine deaminase) gene, the others
were probably caused by AID-independent mechanisms. As
none of the C-residues in the miR-142 mutants described in
the present paper confers to the WRCY (tryptophan–
arginine–cysteine–tyrosine) motif used by AID, we assume
that the mutations were not caused by AID but by another
mechanism active in DLBCL. In that study, the presynaptic
cytomatrix protein (PCLO, piccolo) gene had the highest
number of cases with 17 (32%) of 55 patients showing 23
different mutated sites in the PCLO gene, while other genes
had lower but still significant numbers of changes within the
genes analyzed. The findings by Lohr et al. reinforce the
notion that the same set of genes is mutated in DLBCL as
previously described by Morin et al. [54] and Pasqualucci
et al. [55]. Thus, miR-142 can be added to the growing
number of genes that are mutated in DLBCL.
In our previous study on miRNA expression in DLBCL,
we found that both miR-142-3p and -5p were expressed at
comparable levels (1.1% and 0.8%, respectively, of the total
miRNA count) and they may therefore be of equal impor-
tance for the regulation of cellular targets [24]. A compari-
son of the miR-142-5p levels in Burkitt’s lymphoma versus
DLBCL showed that primary Burkitt’s lymphoma expresses
significantly less miR-142-5p than primary DLBCL [56].
Since no targets are known for miR-142-5p, we can only
speculate about the consequences of the mutations affecting
miR-142-5p. It might be possible that both miR-142-3p
and -5p are involved in the regulation of pathways that
eventually converge at (a) final target(s). As described by
Wu et al. [26], miR-142-3p appears to be a negative regula-
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tor of cell growth. In addition, the putative tumor suppres-
sor nasopharyngeal carcinoma-associated gene 6 (NGX6),
when expressed in colon carcinoma cell lines, induced the
expression of miR-142-3p, whereas miR-146a, which is
known to be induced via NFkb by the EBV oncogene
LMP1 [57], was reduced by NGX6 [58]. Further experi-
ments will be necessary to analyze the function of miR-142-
3p and -5p for lymphoma cell growth. Likewise, it is
important to identify targets for miR-142-5p. At present,
we favor the idea that the mutations within either miR-
142-3p or -5p result in a loss of function, which might
result in a growth stimulation in DLBCL.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Schematic representation of the potential bind-
ing sites for miR-142-m1 and miR-142-m2 in the ZEB1
and ZEB2 3′ UTRs in the luciferase reporter constructs.
The predicted binding sites, the seed sequences, and the
mutated seed sequences are shown.
Figure S2. The EBV miRNAs ebv-miR-BART7 and ebv-
miR-BART22 do not regulate the ZEB2 3′ UTR. The
empty luciferase reporter construct (left panel) or the
pMIR reporter containing the wild-type ZEB2 3′ UTR
(right panel) was coexpressed with vectors for ebv-miR-
BART7 or ebv-miR-BART22. Coexpression of pSG5 served
as control. Mean values were derived from three indepen-
dent experiments carried out in duplicate (± SEM).
Figure S3. Northern blot analysis of the miR-142-mutants
-m3, -m4, -5, and m10. The indicated mutants were
expressed in HEK 293T cells and assayed in a Northern
blot using the indicated probes that perfectly matched the
mutated miRNAs. The bottom lane shows the band of
the tRNA input control.
Figure S4. Comparison of transiently transfected miR-
142-5p mutants with endogenous miR-142-5p. HEK293T
cells were transiently transfected with empty psg5 vector
and the mutants m1, m3, m7, and m9 as indicated. RNA
derived from the U2932 cell line was analyzed in parallel.
As shown in Figure 6, the miR-142-5p-wt probe did not
yield a signal for m3 or m7. The bottom lane shows the
band of the tRNA input control.
Figure S5. Downregulation of the ZEB2 protein by miR-
142-3p mutant m1. HEK 293T cells were transfected with
empty pSG5 vector, pSG5-miR-142-3p-wt or the m1
mutant as indicated. Shown are the individual experi-
ments used for the statistical analysis depicted in Fig-
ure 4. The levels of b-actin stained on the same blot were
used as input control. The relative downregulation, shown
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below each blot, was determined by scanning of the blots
and then compared to the b-actin input control using the
“Quantity One!” program, BioRad, Heidelberg, Germany.
Table S1. Features of the tumours with mutations in
miR-142 (OS: overall survival; BA: break-apart assay; cell
of origin: determined according to Ref. 36).
Table S2. miR-142 mutations found in 56 DLBCLs.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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